|
| |
Cell GenesysCell Genesys is a leader in the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company has a broad portfolio of clinical stage product development programs, the largest patent portfolio in the gene therapy field, proprietary gene delivery technologies, and a strong balance sheet, all of which have helped position Cell Genesys as a leader in gene therapy. The company is conducting clinical trials in multiple types of cancer utilizing two of its three product platform technologies--GVAX® cancer vaccines and oncolytic virus therapies. Cell Genesys' gene therapy technologies, the company's third product platform, are being evaluated in preclinical programs for multiple types of cancer. The company's majority-owned subsidiary, Ceregene, Inc., is focused on the development of gene therapies for neurologic disorders. Cell Genesys also continues to hold approximately nine million shares of common stock in its former subsidiary, Abgenix, Inc.
| Contact Details: |
| 500 FORBES BOULEVARD |
| SOUTH SAN FRANCISCO |
| CALIFORNIA |
| 94080 |
| United States of America |
| Tel: | 650.266.3000 |
| Fax: | 650.266.3010 |
| Email: | IR@cellgenesys.com |
| WWW: | www.cellgenesys.com/
|
|
Loading...
|
Recent Publications by Cell Genesys: |  |
Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Ad5/35 chimeric oncolytic viruses (OVs) have earlier been shown to... | 30th September, 2009
| Cell Genesys Inc, South San Francisco, CA 94080, USA.
| Cancer Gene Ther. 2009 May;16(5):383-92. Epub 2008 Nov 14.
DOI Direct Link |
Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Clinical studies of cell-based immunotherapies have included both... | 12th August, 2009
| Cell Genesys Inc., South San Francisco, CA, USA.
| Clin Immunol. 2009 Nov;133(2):184-97. Epub 2009 Aug 7.
DOI Direct Link |
Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
The limited efficacy of adenovirus type 5 (Ad5)-based oncolytic viruses... | 4th July, 2009
| Cell Genesys, South San
| Hum Gene Ther. 2009 Oct;20(10):1201-13.
DOI Direct Link |
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
PURPOSE: The purpose of the present study was to evaluate granulocyte... | 15th April, 2009
| Cell Genesys, Inc., South San Francisco, California 94080, USA.
| Clin Cancer Res. 2009 Mar 1;15(5):1623-34. Epub 2009 Feb 10.
DOI Direct Link |
Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.
Oncolytic adenoviral vectors that express immunostimulatory transgenes are... | 11th April, 2009
| Cell Genesys, Inc., 500 Forbes Blvd., South San Francisco, CA 94080, USA.
| J Virol. 2009 Apr;83(8):3450-62. Epub 2009 Feb 4.
DOI Direct Link |
→View more Cell Genesys research publications. |
Press Releases on Cell Genesys:
|
 |
| New Report Just Published: World Prostate Cancer Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Prostate Cancer Therapeutics Market
http://www.reportlinker.com/p0119471/World
|
| Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease |
27th May, 2009 |
Ceregene, Inc. |
-- Longer term follow-up indicates modest efficacy in primary and related endpoints --
SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a
|
| Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health |
4th November, 2008 |
Ceregene, Inc. |
SAN DIEGO, Nov. 4 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical
company, today announced that the University of California, San Diego (UCSD)
has received a $5.4 million grant from the
|
| Generic Erosion Will Constrain Prostate Cancer Drug Market, Resulting in Annual Growth of Less Than 2 Percent Through 2012 |
3rd June, 2008 |
Decision Resources |
WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that generic erosion will
|
| Ontogen Announces Formation of Oncology Advisory Group |
1st January, 1970 |
Ontogen |
Ontogen Announces Formation of Oncology Advisory Group
CARLSBAD, Calif., April 3 /PRNewswire/ -- Ontogen Corporation today
announced
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 23 individuals from Cell Genesys using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 565 times since April 2007, the link to the organisation's website has been followed 69 times Recent Search Terms used to find this page: 500 forbes blvd genesys | geneasys patents | Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity patent | . Search for more companies in SOUTH SAN FRANCISCO Search for more companies in CALIFORNIA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Cell Genesys |
